

Transcript Details

This is a transcript of an educational program. Details about the program and additional media formats for the program are accessible by visiting: <https://reachmd.com/programs/medical-industry-feature/treating-severe-eosinophilic-asthma-with-an-autoinjector-a-patients-perspective/12693/>

ReachMD

www.reachmd.com
info@reachmd.com
(866) 423-7849

Treating Severe Eosinophilic Asthma With an Autoinjector: A Patient's Perspective

ReachMD Announcer:

Welcome to ReachMD. This Medical Industry Feature titled, "What Could the Autoinjector Mean to your Patients?", is sponsored by GSK. Intended for US HCP audience only. See full Important Safety Information and Prescribing Information for NUCALA (mepolizumab) in the Related Content section below. For information on how to use the Autoinjector, please see NUCALA.com/howto.

Announcer:

What could the Autoinjector mean to your patients?

NUCALA (mepolizumab) is indicated for the add-on maintenance treatment for patients 6 years and older with severe eosinophilic asthma.

NUCALA is not indicated for acute bronchospasm or status asthmaticus and should not be administered to those with a history of hypersensitivity to mepolizumab or excipients in the formulation.

Patient:

What does the Autoinjector mean to me? A lot, actually.

Ever since my doctor recommended at-home administration of NUCALA for my severe eosinophilic asthma, there have been some nice changes.

[background car noise]

Instead of spending time driving to the doctors for my injection, I'm spending time on the driving range.

[background golf noise]

Instead of sitting in the waiting room, I'm sitting in my living room.

And instead of planning an appointment for my injection, I'm planning a weekend downtown.

[background writing noise]

I wasn't sure about it at first, but once my doctor showed me how to use it... I was all for it.

Announcer:

NUCALA may cause hypersensitivity reactions, such as anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, and rash.

Herpes zoster has occurred. Consider vaccination if medically appropriate.

Do not stop systemic or inhaled corticosteroids abruptly.

Treat pre-existing helminth infections before starting NUCALA.

Most common adverse reactions include headache, injection site reactions, back pain, and fatigue.

Data on pregnancy exposures are insufficient to inform on drug-associated risk. A pregnancy registry monitors pregnancy outcomes.

Learn more at NucalaTreatmentOptions.com

ReachMD Announcer:

NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

NUCALA injection is available as a 100-mg/mL vial, Autoinjector, and prefilled syringe.

At home administration for patients aged 12 years and older.

This program was sponsored by GSK. If you missed any part of this discussion, visit ReachMD.com/industry-feature. This is ReachMD. Be part of the knowledge.

Trademarks are owned by or licensed to the GSK group of companies.

©2021 GSK or licensor.

MPLAUDI210007 September 2021

Produced in USA.